EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Wharton’s jelly and osteoarthritis of the knee

Adarsh Aratikatla, Nicola Maffulli, Manu Gupta, Ishana A Potti, Anish G Potty, Ashim Gupta

British Medical Bulletin · 13.03.2024 · 149 (1) · 13-31

DOI: 10.1093/bmb/ldad030 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift British Medical Bulletin, online erschienen am 07.12.2023. Verfasst von Adarsh Aratikatla und 5 weiteren Autor:innen. Beteiligte Einrichtung: The Royal College of Surgeons in Ireland, Dublin D02 YN77, Ireland. Hauptthemen laut MEDLINE: Mesenchymal Stem Cells, Osteoarthritis, Knee, Wharton Jelly. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction The existing treatment modalities for knee osteoarthritis (OA) do not actually address the pathology. Biological therapies, including those using material derived from perinatal tissues, represent a ground-breaking approach to alleviating the symptoms of OA of the knee. Source of data Current scientific literature published in PubMed (MEDLINE), Embase and Scopus databases. Trials registered in various clinical trial databases. Areas of agreement Perinatal tissues including Wharton’s jelly (WJ) and associated mesenchymal stem cells (MSCs) can be used for the management of knee OA. Areas of controversy The efficacy of WJ and associated MSCs in the management of knee OA is still controversial. Growing points The use of WJ and associated MSCs in the management of knee OA is safe and appears to be effective. Areas timely for developing research The present published evidence suggests that WJ tissue and associated MSCs offer an encouraging alternative for the management of knee OA. The published in vitro, preclinical and clinical investigations demonstrate the therapeutic potential of WJ and promote further research in this field to provide symptomatic relief to patients suffering from OA, aiming also to regenerate the osteoarthritic hyaline cartilage, with disease-modifying effects. Future adequately powered randomized controlled trials should be undertaken to establish whether WJ is helpful in the management of OA of the knee.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Mesenchymal Stem CellsOsteoarthritis, KneeWharton JellyHumansCell DifferentiationUmbilical Cord

Stichwörter der Autor:innen

Wharton’s jellyknee osteoarthritisosteoarthritisperinatal tissueregenerative medicineumbilical cord

Autor:innen und Institutionen

  • The Royal College of Surgeons in Ireland, Dublin D02 YN77, Ireland.
  • Department of Musculoskeletal Disorders, School of Medicine and Surgery, University of Salerno, Fisciano 84084, Italy.
  • Department of Trauma and Orthopaedics, Ospedale Sant' Andrea, Sapienza University of Rome, Rome, Italy.
  • Barts and the London School of Medicine and Dentistry, Centre for Sports and Exercise Medicine, Queen Mary University of London, London E1 4DG, UK.
  • School of Pharmacy and Bioengineering, Keele University School of Medicine, Stoke on Trent ST5 5BG, UK.
  • Polar Aesthetics Dental & Cosmetic Centre, Noida, Uttar Pradesh 201301, India.

Zitieren

APA

Aratikatla, A., Maffulli, N., Gupta, M., Potti, I. A., Potty, A. G., & Gupta, A. (2024). Wharton’s jelly and osteoarthritis of the knee. British Medical Bulletin, 149(1), 13-31. https://doi.org/10.1093/bmb/ldad030

Vancouver

Aratikatla A, Maffulli N, Gupta M, Potti IA, Potty AG, Gupta A. Wharton’s jelly and osteoarthritis of the knee. British Medical Bulletin. 2024;149(1):13-31. doi:10.1093/bmb/ldad030

BibTeX
@article{Aratikatla2024,
  author = {Aratikatla, Adarsh and Maffulli, Nicola and Gupta, Manu and Potti, Ishana A and Potty, Anish G and Gupta, Ashim},
  title = {Wharton’s jelly and osteoarthritis of the knee},
  journal = {British Medical Bulletin},
  year = {2024},
  volume = {149},
  number = {1},
  pages = {13--31},
  doi = {10.1093/bmb/ldad030}
}
Kostenlos starten →